Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:protein
gptkb:drug hormone |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:Russia
|
| gptkbp:ATCCode |
H01AX27
|
| gptkbp:brand |
Reasanz
|
| gptkbp:CASNumber |
161481-09-6
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:compatibleWith |
gptkb:European_Union
gptkb:United_States |
| gptkbp:developedBy |
gptkb:Novartis
|
| gptkbp:hasClinicalTrialName |
RELAX-AHF
RELAX-AHF-2 |
| gptkbp:hasMolecularFormula |
C256H408N74O76S6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Relaxin (serelaxin)
|
| gptkbp:isPeptide |
true
|
| gptkbp:isRecombinantFormOf |
human relaxin-2
|
| gptkbp:mechanismOfAction |
vasodilation
increases renal blood flow reduces systemic vascular resistance |
| gptkbp:molecularWeight |
5987 Da
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
dizziness headache hypotension |
| gptkbp:targetsReceptor |
relaxin family peptide receptor 1 (RXFP1)
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:usedFor |
acute heart failure
|
| gptkbp:bfsParent |
gptkb:Corthera
|
| gptkbp:bfsLayer |
7
|